MX390529B - Metodos para tratar infecciones bacterianas - Google Patents

Metodos para tratar infecciones bacterianas

Info

Publication number
MX390529B
MX390529B MX2019008281A MX2019008281A MX390529B MX 390529 B MX390529 B MX 390529B MX 2019008281 A MX2019008281 A MX 2019008281A MX 2019008281 A MX2019008281 A MX 2019008281A MX 390529 B MX390529 B MX 390529B
Authority
MX
Mexico
Prior art keywords
methods
bacterial infections
treating bacterial
urinary tract
tract infection
Prior art date
Application number
MX2019008281A
Other languages
English (en)
Spanish (es)
Other versions
MX2019008281A (es
Inventor
David C Griffith
Elizabeth E Morgan
Jeffrey S Loutit
Karen Fusaro
Michael N Dudley
Olga Lomovskaya
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX390529(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of MX2019008281A publication Critical patent/MX2019008281A/es
Publication of MX390529B publication Critical patent/MX390529B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019008281A 2017-01-09 2018-01-08 Metodos para tratar infecciones bacterianas MX390529B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01
PCT/US2018/012839 WO2018129479A1 (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2019008281A MX2019008281A (es) 2019-12-02
MX390529B true MX390529B (es) 2025-03-20

Family

ID=62791302

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008281A MX390529B (es) 2017-01-09 2018-01-08 Metodos para tratar infecciones bacterianas
MX2022001704A MX2022001704A (es) 2017-01-09 2019-07-09 Metodos para tratar infecciones bacterianas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001704A MX2022001704A (es) 2017-01-09 2019-07-09 Metodos para tratar infecciones bacterianas.

Country Status (21)

Country Link
US (1) US12478606B2 (https=)
EP (2) EP3565551B1 (https=)
JP (2) JP7436206B2 (https=)
KR (2) KR102768209B1 (https=)
CN (1) CN110402139A (https=)
AU (1) AU2018205327B2 (https=)
BR (1) BR112019014089A2 (https=)
CA (1) CA3048650A1 (https=)
CL (2) CL2019001918A1 (https=)
CO (1) CO2019008575A2 (https=)
DK (1) DK3565551T3 (https=)
ES (1) ES2979266T3 (https=)
FI (1) FI3565551T3 (https=)
HU (1) HUE066805T2 (https=)
MX (2) MX390529B (https=)
NZ (1) NZ755141A (https=)
PH (1) PH12019501606A1 (https=)
PL (1) PL3565551T3 (https=)
PT (1) PT3565551T (https=)
SG (1) SG11201906226YA (https=)
WO (1) WO2018129479A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法
US11376237B2 (en) 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
WO2022026993A1 (en) * 2020-07-27 2022-02-03 Northwestern University Antimicrobial choice algorithm for urinary tract infections
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy
CN121419770A (zh) * 2023-05-02 2026-01-27 希普拉有限公司 包含抗细菌剂的药物组合及其组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105393011A (zh) * 2013-05-15 2016-03-09 舍弗勒技术股份两合公司 减少阻力的离合器板
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法

Also Published As

Publication number Publication date
KR102768209B1 (ko) 2025-02-18
US20190336475A1 (en) 2019-11-07
NZ755141A (en) 2023-01-27
MX2022001704A (es) 2022-03-11
EP3565551A4 (en) 2020-09-23
JP2020504154A (ja) 2020-02-06
SG11201906226YA (en) 2019-08-27
US12478606B2 (en) 2025-11-25
CL2020001886A1 (es) 2020-12-18
PH12019501606A1 (en) 2020-06-15
PL3565551T3 (pl) 2024-09-23
WO2018129479A1 (en) 2018-07-12
AU2018205327B2 (en) 2023-11-30
CL2019001918A1 (es) 2020-02-14
KR20240133785A (ko) 2024-09-04
CN110402139A (zh) 2019-11-01
BR112019014089A2 (pt) 2020-02-04
JP2023012538A (ja) 2023-01-25
CO2019008575A2 (es) 2019-08-30
FI3565551T3 (fi) 2024-06-18
DK3565551T3 (da) 2024-06-17
CA3048650A1 (en) 2018-07-12
ES2979266T3 (es) 2024-09-25
HUE066805T2 (hu) 2024-09-28
AU2018205327A1 (en) 2019-07-25
KR20190104385A (ko) 2019-09-09
EP3565551A1 (en) 2019-11-13
JP7436206B2 (ja) 2024-02-21
MX2019008281A (es) 2019-12-02
PT3565551T (pt) 2024-06-14
EP4212157A1 (en) 2023-07-19
EP3565551B1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
CL2020001886A1 (es) Métodos para tratar infecciones bacterianas. (divisional solicitud 201901918)
MX2024009339A (es) Biomarcadores utiles en el diagnostico de infecciones bacterianas y virales.
MX2015010190A (es) Metodos de tratamiento topico para infecciones microbianas.
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
UY36701A (es) Tratamiento contra el cáncer por manipulación de la microflora comensal
MX2017014806A (es) Conjugados oligonucleotido- peptido.
BR112016017690A2 (pt) Tratamentos para acne resistente
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
MX376284B (es) Una composición que comprende un agente antibiótico y un agente dispersante o un agente antiadhesivo.
BR112014008666A8 (pt) acelerando recuperação de músculo após a atrofia muscular ter induzido imobilização
FR2969495B1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
WO2018094023A3 (en) Cyclic dipeptides and wound healing
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
PH12017501300A1 (en) Novel iodophor composition and methods of use
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
EA201290689A1 (ru) Лечение стрептококковых инфекций
EA201891033A1 (ru) Композиция с благоприятным действием на кожу на основе растворителя, содержащего гидроксигруппы
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2020003660A (es) Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.
MX2019000849A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MY197898A (en) A composition comprising pic for treatment of cancer
CL2012003202A1 (es) Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion.